RxDoctor Payments Data

Nicholas Depace, MD

Cardiovascular Disease · Sewell, NJNPI 1467496687

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 67 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$209
  • Medtronic$206
  • AstraZeneca$198
  • Novo Nordisk$155
  • Boston Scientific$144
  • Novartis$90
  • plus $478 from 13 others

What the payments were for

  • Food & beverage$1,45799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$916,852
Medicare patients
930
Services billed
10,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$398,432
XareltoRivaroxaban154$186,643
Droxidopa226$174,532
FarxigaDapagliflozin Propanediol78$103,588
OzempicSemaglutide76$81,213
VascepaIcosapent Ethyl94$53,122
Midodrine Hcl549$41,330
EntrestoSacubitril/Valsartan19$34,260
Icosapent Ethyl61$23,330
NexletolBempedoic Acid20$19,953
Praluent PenAlirocumab11$14,915
Rosuvastatin Calcium578$10,127
Pyridostigmine Bromide206$10,021
Breo ElliptaFluticasone/Vilanterol18$8,572
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$59$186,643154 claims
AstraZenecaFarxiga$198$103,58878 claims
Novo NordiskOzempic$155$81,21376 claims
NovartisEntresto$90$34,26019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →